• Users Online: 87
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2017  |  Volume : 1  |  Issue : 1  |  Page : 8-10

Pimavanserin – drug review


Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India

Correspondence Address:
Nithya Gogtay
Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Parel, Mumbai - 400 012, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/aip.aip_12_17

Get Permissions

Pimavanserin is a drug with a novel mechanism of action that has recently received approval management of patients with Parkinson's disease psychoses [PDP]. It is a 5HT2A inverse agonist that has been shown in a randomized controlled trial to be superior to placebo and also reasonably safe and effective. It significantly reduces positive symptoms seen in Parkinson's disease patients with psychosis with no evident impairment of motor function. It offers hope for patients and caregivers with this otherwise distressing and difficult to manage condition and has also paved the way for the use of 5HT2A inverse agonists in this condition.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed290    
    Printed30    
    Emailed0    
    PDF Downloaded76    
    Comments [Add]    

Recommend this journal